UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 85 filers reported holding UROGEN PHARMA LTD in Q2 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1 | – | 48 | 0.0% | 0.00% | – |
| Q2 2023 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q1 2023 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q4 2022 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 48 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 48 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 48 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 48 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 48 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 48 | -59.3% | 0.00% | – |
| Q3 2020 | $2,000 | -93.8% | 118 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $32,000 | +1500.0% | 118 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | -33.3% | 118 | 0.0% | 0.00% | – |
| Q4 2019 | $3,000 | 0.0% | 118 | -11.3% | 0.00% | – |
| Q3 2019 | $3,000 | -40.0% | 133 | -11.3% | 0.00% | – |
| Q2 2019 | $5,000 | -16.7% | 150 | 0.0% | 0.00% | – |
| Q1 2019 | $6,000 | – | 150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |